Karen Liu

Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015.

Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015.

Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015.